The US FDA has approved losartan potassium oral suspension for treating hypertension in patients aged six years and older, reducing the risk of stroke in patients with hypertension and left ventricular hypertrophy, and treating diabetic nephropathy in patients with type 2 diabetes. Losartan potassium is an angiotensin II receptor blocker and the first and only FDA-approved ready-to-use oral liquid losartan. Clinical evidence In clinical trials, losartan effectively reduced blood pressure in adult and pediatric patients with hypertension compared to a placebo.
In a clinical trial involving hypertensive patients with left ventricular hypertrophy, losartan reduced the risk of cardiovascular death, nonfatal stroke, and nonfatal myocardial infarction by 13% compared to atenolol. Additionally, it demonstrated a 25% reduction in stroke risk. In a study involving type 2 diabetes patients with…
